ZLAB Share Price Performance
US$19.27
-16.64 (-46.34%)
61.1% undervalued intrinsic discount
US$49.49
Fair Value
Price US$19.27
AnalystConsensusTarget US$49.49
AnalystLowTarget US$20.42
AnalystHighTarget US$55.00
Fair ValueUS$49.49
Share Pricen/a
Zai Lab Limited Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 19 Fair Values set on narratives written by author
ZLAB Community Narratives
AN
Fair Value US$49.49 61.1% undervalued intrinsic discount
Expanding China Healthcare And Global Pipelines Will Broaden Patient Options
0users have liked this narrative
0users have commented on this narrative
12users have followed this narrative
AN
Fair Value US$20.42 5.6% undervalued intrinsic discount
China Price Controls Will Limit Growth But Create Opportunity
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value US$55 65.0% undervalued intrinsic discount
China And Asia-Pacific Demographics Will Transform Biopharma Markets
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
China And Asia-Pacific Demographics Will Transform Biopharma Markets
Key Takeaways Accelerated product launches, innovation, and strategic market expansion position Zai Lab for rapid revenue and margin growth beyond current analyst expectations. Strong operational model and international focus could transform Zai Lab into a leading global biopharma player, attracting premium valuations and partnership opportunities.Read more
29
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$55
65.0% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Profit Margin
7.07%
Future PE
115.75x
Price in 2029
US$68.72
China Price Controls Will Limit Growth But Create Opportunity
Key Takeaways Stricter regulatory controls, pricing pressure, and reimbursement hurdles in China threaten sustainable revenue growth and delay earnings from new drug launches. Heavy reliance on in-licensed assets and intense competition exposes the company to generic threats, partner risks, and rising costs, impacting long-term profitability.Read more
9
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$20.42
5.6% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Profit Margin
16.94%
Future PE
24.28x
Price in 2029
US$25.51
Expanding China Healthcare And Global Pipelines Will Broaden Patient Options
Key Takeaways Robust product pipeline and operational improvements are set to diversify revenue and increase profitability through expanded market access and AI-driven cost efficiencies. Growing demand for innovative therapies and supportive regulatory conditions are expected to accelerate volume growth, market penetration, and long-term sales.Read more
127
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
12users have followed this narrative
AN
US$49.49
61.1% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Profit Margin
12.47%
Future PE
50.9x
Price in 2028
US$61.75
Trending Discussion
Recently Updated Narratives
AN
ZLAB: China Approvals And Pipeline Execution Will Support Future Upside Potential
Fair Value: US$55 65.0% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
ZLAB: Mixed Coverage And New Approvals Will Shape A Measured Re Rating
Fair Value: US$20.42 5.6% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
ZLAB: Diversified Pipeline Is Expected To Drive Long-Term Market Expansion
Fair Value: US$49.49 61.1% undervalued intrinsic discount
12 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Zai Lab Limited Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -1.57
- 10.47%
- -38.15%
- 28.6%
About ZLAB
- Founded
- 2013
- Employees
- 1784
- CEO
- WebsiteView website
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. Zai Lab Limited has license and collaboration agreements with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure Ltd. to develop and commercialize Tumor Treating Fields; Deciphera Pharmaceuticals, LLC to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx BV to develop and commercialize efgartigimod; Turning Point Therapeutics, Inc. to develop and commercialize products containing repotrectinib; Entasis Therapeutics Holdings Inc. to develop and commercialize Durlobactam with Sulbactam; and Karuna Therapeutics, Inc. to develop and commercialize Xanomeline and trospium chloride, as well as strategic collaboration with Pfizer Inc. for Tisotumab Vedotin. The company was incorporated in 2013 and is based in Pudong, China.
